Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
34 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Weizmann Institute of Science (WIS) is a research institute that offers research services in the field of natural and exact sciences. The institute offers programs that include graduate programs, post graduate programs, scientific research, academic affairs, science education, research and development. It carries out research and education through its different departments and faculties in the field of biology, biochemistry, physics, chemistry, mathematics and computer science. WIS also offers research services through division of research services, biological services unit and veterinary resources among others.

Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent de

  
Source:
Document ID
GDPH71137D
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Weizmann Institute of Science, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Weizmann Institute of Science, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Weizmann Institute of Science, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Weizmann Institute of Science, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Weizmann Institute of Science, Medical Devices Deals, 2010 to YTD 201691
Weizmann Institute of Science, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016102
Weizmann Institute of Science, Pharmaceuticals &Healthcare, Deal Details1219
  Partnerships121
    Galmed Pharma Enters into Research Agreement with Yeda Research and Development121
    Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela131
    XL-protein Enters into Collaboration Agreement with Yeda Research141
    Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science151
    Immune Pharma Enters Into Co-Development Agreement With Yeda Research161
    Abbott Labs Enters Into Co-Development Agreement With Yeda Research171
  Licensing Agreements181
    Merck Enters into Licensing Agreement with Weizmann Institute of Science181
    Stem Cell Medicine Enters into Licensing Agreement with Ramot at Tel Aviv University and Yeda Research and Development191
    TxCell Exercises Option for Licensing Agreement with Yeda Research and Development201
    Tikcro Technologies Emends its Research and Licensing Agreement with Yeda Research and Development211
    Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development221
    PsychoGenics Enters into Licensing Agreement with Yeda Research and Development231
    XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1241
    miCure Therapeutics Enters into Licensing Agreement with Yeda Research251
    PROLOR Biotech Enters Into Licensing Agreement With Yeda Research262
    XTL Biopharma Enters into Licensing Agreement with Yeda Research and Development281
    Raptor Pharma Enters Into Licensing Agreement With Weizmann Institute And Niigata University292
Weizmann Institute of Science - Key Competitors311
Key Employees321
Locations And Subsidiaries331
  Head Office331
  Other Locations &Subsidiaries331
Appendix341
  Methodology341
  About GlobalData341
  Contact Us341
  Disclaimer341

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Weizmann-Institute-of-Science-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6669>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Weizmann-Institute-of-Science-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6669>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research